Utility of the predictors of coronary heart disease mortality in a longitudinal study of elderly Finnish men aged 65 to 84 years is dependent on context defined by Apo E genotype and area of residence Stengård JH, Kardia SL, Tervahauta M, Ehnholm C, Nissinen A, Sing CF. Utility of the predictors of coronary heart disease mortality in a longitudinal study of elderly Finnish men aged 65 to 84 years is dependent on context defined by Apo E genotype and area of residence Clin Genet 1999: 56: 367 -377. © Munksgaard, 1999 A common assumption underlying most genetic studies is that individuals with different genotypes respond similarly to exposure to internal (epigenetic and background genotype effects) and external (ecological) environments. Here we evaluate whether this assumption is true in individuals with different genotypes of the gene coding for the apolipoprotein E (Apo E) molecule, an important determinant of the metabolic fate of plasma lipids and lipoproteins. We addressed whether the utility of known risk factors of coronary heart disease (CHD) in the prediction of CHD death in a 5-year follow-up is the same for the two most common Apo E genotypes, o3/3 and o4/3, in two cohorts of elderly Finnish men (age at baseline: 65 -84 years), one in Eastern and the other in Southwestern Finland. The CHD mortality rate was higher in the o4/3 than in the o3/3 genotype in both cohorts (11.1 versus 7.8%, Pr =0.281 in the Eastern cohort and 19.6 versus 8.2%, Pr = 0.002 in the Southwestern cohort). In the Eastern cohort, serum high density lipoprotein (HDL) cholesterol level was identified as a strong predictor of CHD death in the o3/3 genotype (b= −2.155, Pr = 0.019). In the Southwestern cohort, age (b= 0.139, Pr = 0.006), body mass index (BMI) (b =0.149, Pr = 0.016), and serum total cholesterol level (b= 0.453, Pr = 0.051) were identified as strong predictors in the o3/3 genotype, as were smoking (b = 0.236, Pr = 0.008) and BMI (b= −0.124, Pr= 0.057) in the o4/3 genotype. The latter observation indicates that in Southwestern Finland the probability of CHD death decreases with increasing BMI in elderly men with the o4/3 genotype, while in their counterparts with the o3/3 genotype the risk increases with increasing BMI. This difference was statistically significant (Pr = 0.002). These observations clearly argue against the assumption that individuals with different genotypes respond similarly to exposures to internal and/or external environments. These observations are consistent with a complex pathobiology of CHD involving biochemical and physiological agents that are under the influence of interactions between genetic and environmental factors. Information about these interactions is necessary for developing a more precise risk assessment and ultimately to improve public health and clinical strategies to prevent this devastating disease both at the individual and population levels.
There is ample evidence that interindividual differences in levels of biochemical and physiological traits, which are involved in the regulation of lipid metabolism, glucose homeostasis, blood pressure, and hemostasis, contribute significantly to interindividual variation in the initiation, progression, and severity of atherosclerosis (1, 2) . Knowledge about levels of these traits is widely used to predict the risk of coronary heart disease (CHD), which is a clinically important manifestation of atherosclerosis. In clinical practice, and in public health programs, individuals with extreme values of the known risk factors are considered to be candidates for lifestyle alterations and therapeutic interventions.
Apolipoprotein E (Apo E), a structural constituent of various plasma lipoprotein particles, functions as an important determinant of the metabolic fate of plasma lipids and lipoproteins (3, 4) . Three major Apo E isoforms, o 2 , o 3 , and o 4 have been described (3, 4) . Allelic variations responsible for this protein polymorphism, denoted o 2 , o 3 , and o 4 , are associated with variation in, and covariation between, quantitative measures of lipid and lipoprotein metabolism (4 -9) and the presence of CHD (3, 4) in many cross-sectional epidemiological and clinical studies. Previously we reported that the common genotypes of the gene that codes for the three Apo E isoforms contribute to the prediction of CHD death among elderly Finnish men in a 5-year prospective follow-up (10) . The influence of the Apo E polymorphism on the levels of plasma lipids and apolipoproteins may depend, however, on the levels of other risk factors such as body size, gender, and smoking status (11) . Such dependency suggests that the information about CHD that a risk factor provides may vary among the Apo E genotypes. In this study we address this possibility by asking whether the utility of known CHD risk factors in the prediction of CHD death in a 5-year follow-up is the same for the two most common Apo E genotypes o3/3 and o4/3 in two cohorts of elderly Finnish men, one representing Eastern and the other Southwestern Finland.
Methods Sample
The Seven Countries Study, which included Finland, was initiated in the late 1950's to study cardiovascular disease mortality and morbidity and related risk factor levels in different populations (12, 13) . The original Finnish cohorts consisted of men born between 1900 and 1919 and living in two geographically defined rural areas, one in Eastern (n= 823) and the other in Southwestern Finland (n=888). Of these 1711 men, 766 (45%) were still alive in 1984, when baseline assays for the current study were performed. Knowledge about both the Apo E genotype and risk factor levels was available from 625 (82%) of these men. In this sample, 559 (89%) had either the o3/3 or the o4/3 genotype. The Eastern cohort was comprised of 256 men, of whom 193 (75%) had the o3/3 genotype. The Southwestern cohort was comprised of 303 men, of whom 196 (65%) had the o3/3 genotype.
At the time of the follow-up survey in 1989, of the 559 men who had either the o3/3 or the o4/3 genotype, 387 (183 in the Eastern cohort and 204 in the Southwestern cohort) were still alive and 172 (73 (29%) in the Eastern cohort and 99 (33%) in the Southwestern cohort) had died during the 5-year follow-up period. The vital status of each man was ascertained through personal contacts, except for 11 men whose vital status was ascertained through the Finnish Population Registry. Death certificates and hospital records were obtained for all the deceased men and the cause of death was coded according to fixed criteria (13) .
Study protocol
Both baseline and follow-up surveys of each geographic region were conducted during the same month of the year, October in the East and November in the Southwest. Complete details of the study protocols of the 1984 baseline survey and the follow-up survey in 1989, are given elsewhere (14, 15) . All participants fasted for at least 4 h before their visit to the clinic (mean fasting time was 13 h, standard deviation 5 h). At the clinic, blood samples were drawn from the antecubital vein for laboratory analyses. Body weight was measured to the nearest 0.1 kg in light undergarments. Height was measured only in 1959, when the men were first seen in connection with the Seven Countries Study. This height was used to calculate body mass index (BMI, kg/m 2 ), a measure of body size used in the current analyses.
Smoking status was assessed using a standard questionnaire (13) . Participants were classified into two categories: smokers of cigarettes, cigars or pipes, and non-smokers. Participants who had not smoked for more than 1 year before the survey were classified as non-smokers.
Blood pressure was measured by a trained nurse. After at least a 5 min rest at the end of clinical examination, two successive readings were taken from the right arm using a mercury manometer with a 12 ×33.5 cm cuff. Readings were taken to the nearest 2 mmHg and complete disappearance of the fifth phase of Korotkoff sounds was recorded as the diastolic pressure. We used the mean values of the two readings for the analyses presented in this study.
Laboratory measurements
Serum total and high density lipoprotein (HDL) cholesterol concentrations were assayed using an enzymatic method (Monotest, Boehringer Mannheim, GmbH, Mannheim, Germany) and an Olli 3000 photometer (Kone Oy, Finland). Total cholesterol was determined from a fresh serum sample (16) . HDL cholesterol was measured after precipitation of very low density lipoprotein (VLDL) and low density lipoprotein (LDL) particles with dextran-magnesium-chloride (16) . Apo E phenotypes were determined using sera stored at −20°C until utilized in 1992. Apo E phenotyping was carried out according to a modification of the method of Havekes et al. (17) , which was based on isoelectric focusing of delipidated serum followed by immunoblotting using rabbit anti-human Apo E antiserum. Apo E genotypes were inferred from the isoform phenotypes.
Statistical analysis
Baseline differences between the carriers of the o3/3 and o4/3 genotypes were tested for statistical significance by the analysis of variance (means) and Bartlett's test (variances) for quantitative risk factors and x 2 -statistics for categorical variables, seperately for the Eastern and the Southwestern cohorts. The cohorts were analyzed separately because there is ample evidence that the natural history of CHD differs between them (12, 13, 18, 19) . The following risk factors were considered in the analysis: age, BMI, systolic and diastolic blood pressure, serum total and HDL cholesterol levels, and smoking status.
The Kaplan-Meier product limit method (20) was used to estimate the Apo E genotype-specific probability of surviving, or if an individual died, not dying from CHD, as a function of time. A logistic regression analysis (21) was employed to estimate the intragenotypic probability of CHD death in a 5-year follow-up using a model where each proposed CHD risk factor was considered in a univariable model, separately for the carriers of the o3/3 and o4/3 genotypes. Each risk factor that was associated with the probability of CHD death within at least one of the two Apo E genotype strata at the Pr5 0.20 level of statistical significance in these analyses was selected for further analyses to assess whether the observed association is homogeneous across the two Apo E genotype strata. This relatively high significance level was selected because the use of a more traditional test criterion (Pr50.05) at this point could result in disregarding risk factors that contribute significantly to the prediction of CHD probability of death when considered in a multivariable model (21) . This analysis was carried out separately for the Eastern and the Southwestern cohorts.
In order to test homogeneity of the observed Apo E genotype-specific associations between the probability of CHD death and a proposed risk factor, we first employed a complete model where the Apo E genotype, a proposed CHD risk factor, and the interaction between the effects of the two Apo E genotypes and levels of the proposed risk factor were considered. The effects of the two Apo E genotypes were included in the model as a binary variable where the o3/3 genotype was coded as 0 and the o4/3 was coded as 1. Interaction between the Apo E genotypes and levels of a CHD risk factor was modeled as a product of this binary variable and the risk factor considered. The logit under this most complete model was parameterized as follows: logit of the probability of CHD death = a+b 1 *o +b 2 *X +b 3 *o*X, where o represents the code of Apo E genotype and X represents the level of the risk factor of interest. Under this parameterization the logit of the probability of CHD death is a+b 2 *X for the carriers of the o3/3 genotype (o= 0) and (a +b 1 ) +(b 2 +b 3 )*X for the carriers of the o4/3 genotype (o =1).
Second, we considered a reduced model, where the parameter b 3 was constrained to 0 and the remaining parameters of the model were re-estimated. In this reduced model the estimate of the parameter a is an estimate of the intercept for the logit in the carriers of the o3/3 genotype, and the sum of the estimates of a and b 1 is an estimate of intercept for the logit in the carriers of the o4/3 genotype. The estimate of the b 2 parameter in this reduced model is an estimate of the slope of the logit shared by both genotype classes. The maximum value of the likelihood of this reduced 'no interaction' model was compared with the maximum value of the likelihood of the complete model, using a likelihood ratio criterion with one degree of freedom to test whether the slopes of the logits were homogeneous among the two genotypes. Rejection of the null hypothesis that a common slope explains these data supports the hypothesis that the ability to predict the probability of CHD death from the level of a risk factor is dependent on the individual's Apo E genotype.
All statistical analyses were performed with the SAS statistical software package. Statistical tests that achieved the Pr 50.05 level of probability were considered to be statistically significant unless otherwise stated.
Results

Comparison of the risk factor levels at baseline between the two common Apo E genotypes
The Apo E genotype-specific means and standard deviations of risk factor levels at baseline are given separately for the Eastern and the Southwestern cohorts in Table 1 . No statistically significant heterogeneity was observed for average age, BMI, serum total and HDL cholesterol, systolic and diastolic blood pressure levels, and proportion of current smokers between the two Apo E genotypes in either cohort. In contrast, variance of age in the Eastern cohort was significantly larger in the carriers of the o3/3 genotype than in the carriers of the o4/3 genotype (Pr= 0.038). The variance of serum total cholesterol in the Southwestern cohort was significantly larger in the carriers of the o4/3 genotype than in the carriers of the o3/3 genotype (Pr=0.008).
Comparison of CHD death between the two common Apo E genotypes
During the 5-year follow-up period, a total of 22 CHD deaths were recorded in the Eastern cohort. Of these, 15 were carriers of the o3/3 genotype (7.8% of the o3/3 individuals) and 7 were carriers of the o4/3 genotype (11.1% of the o4/3 individuals). In the Southwestern cohort, a total of 37 CHD deaths were recorded. Of these, 16 were carriers of the o3/3 genotype (8.2% of the o3/3 individuals) and 21 were carriers of the o4/3 genotype (19.6% of the o4/3 individuals). Comparison of the Kaplan-Meier survival probability curve for the carriers of the o3/3 genotype with the curve for the carriers of the o4/3 genotype indicates that the observed heterogeneity in CHD mortality rates between the two Apo E genotypes in the Eastern cohort was not statistically significant (Pr=0.281) (Fig. 1A) . In contrast, the observed heterogeneity in the CHD mortality rates between genotypes was statistically significant in the Southwestern cohort (Pr =0.002) (Fig. 1B) .
Predictive utility of known risk factors among the carriers of the two common Apo E genotypes
In the Eastern cohort, serum HDL cholesterol was identified as a statistically significant predictor of CHD death in the 5-year follow-up in the o3/3 genotype at the Pr =0.019 level of probability (Table 2) . BMI contributed to the prediction of CHD death at a Pr=0.104 level of statistical sig- Fig. 1 . Illustrations of the Apo E genotype-specific survival probability curves, separately for the Eastern (A) and the Southwestern (B) male cohorts. The Kaplan-Meier product limit method was used to estimate probability of surviving, or if an individual died, not dying from CHD, as a function of time, separately for the o3/3 and o4/3 genotypes in each cohort. The null hypothesis that the curves are homogeneous among the genotypes could not be rejected in the Eastern cohort (Pr = 0.281) while in the Southwestern cohort it was rejected (Pr =0.002). nificance and smoking status at the Pr= 0.128 level of statistical significance. In contrast, among the carriers of the o4/3 genotype, no risk factor was detected as a predictor of CHD death at the Pr5 0.05 level of statistical significance. Serum total cholesterol was the only risk factor that contributed to the prediction of CHD death at the Pr 50.200 level of statistical significance in this genotype class. In the Southwestern cohort, age, BMI, and serum total cholesterol level were identified as significant predictors of CHD death among the carriers of the o3/3 genotype at the Pr = 0.05 level of probability (Table 2 ). In those with the o4/3 genotype, BMI (Pr=0.057), serum total cholesterol (Pr = 0.083), serum HDL cholesterol (Pr= 0.108), and smoking status (Pr=0.008) each contributed to the prediction of CHD death.
Heterogeneity of the predictive utility of different risk factors among the carriers of the two common Apo E genotypes
In the Eastern cohort, the null hypothesis that the slopes of the logits of CHD death are homogeneous across the two common Apo E genotypes was rejected (Pr=0.059) when an association between the probability of CHD death and smoking status was tested in a bivariable model (Table 2) . In this case, the estimate of the slope was negative for the carriers of the o3/3 genotype and positive for the carriers of the o4/3 genotype. No statistically significant heterogeneity (Pr50.05) of the slopes of the logits could be detected in this cohort when BMI and/or serum total and/or HDL cholesterol level were considered as predictors of CHD death.
In the Southwestern cohort, the null hypothesis of the homogeneity of the slopes of the logits of CHD death was rejected (Pr=0.002) in a bivariable model when BMI was considered as a predictor (Table 2) . In this case, the estimate of the slope was positive for the carriers of the o3/3 genotype and negative for the carriers of the o4/3 genotype. The probability of CHD death as a function of BMI based on these estimates in the Southwestern cohort is given in Fig.  2B , separately for the carriers of the o3/3 and o4/3 genotypes. For comparison, CHD death probabili- ties as a function of BMI, based on the estimates obtained in the Eastern cohort, are given in Fig.  2A . No other statistically significant heterogeneity (Pr5 0.05) of the slopes of the logits could be detected in the Southwestern cohort when the other predictors of CHD death (age, serum total and HDL cholesterol levels, and smoking status) were considered separately.
Discussion
It is widely accepted that the relative importance of risk factors in the prediction of CHD endpoints may vary among populations (1, 2, 13 ). There is also accumulating evidence that within a population (level A, Fig. 3 ) there may be subgroups of individuals (levels B -D, Fig. 3 ) which have different risk profiles. Recently subgroups differing in age have attracted particular attention because the predictive power of many risk factors may diminish in the elderly (22 -25) . Here we further considered the subdivision of the population by genotype. Our analysis considers the relative impact of area of residence, age stratification, and the Apo E genotype on the influence of variation in the levels of risk factors on the variation in risk of CHD death. There are both an historical and a practical rationale for considering these hierarchically defined subgroups. Initial observations in the 1950's established that both the average levels of most risk factors and CHD morbidity and mortality rates are different in Eastern Finland and Southwestern Finland (12, 13, 18, 19) . Because the knowledge about the Apo E status was available only from the elderly men, age was considered in the hierarchy prior to the Apo E genotype. The rationale for performing a stratified evaluation of CHD risk is a response to clinical and public health needs to identify individuals (or patients) (level E, Fig. 3 ) who have a similar prognosis and/or who are candidates for similar therapeutic interventions.
Geographic and age-specific differences in the contributions of known risk factors to the prediction of CHD death
This study, together with other studies (10, 22, (26) (27) (28) , demonstrates that the risk factors, which are initially identified as predictors of CHD in middle-aged men, are also predictors in elderly men. The combinations of risk factors that were identified as predictors of CHD death in a 5-year follow-up in Eastern and Southwestern Finland in this study and in our earlier study (10) differ, however, from the combinations reported to be present in these cohorts in the 1950's, when the men were middle-aged (18, 19) . In the latter studies, serum total cholesterol level, smoking, and blood pressure were major predictors of CHD endpoints in both cohorts. In the elderly survivors of these cohorts studied here, none of these risk factors was identified as a predictor of CHD death in Eastern Finland and only serum total cholesterol level and smoking status were predictors in Southwestern Finland (10) at a Pr 50.05 level of statistical significance. A fraction of the observed age and geography-related differences in the predictive power of the CHD risk factors may reflect a difference in the age-specific death rates in the two subpopulations. In the Eastern cohort there has been an excess of individuals who have had extreme high risk factor values and who have died of CHD in the past (12) . Survivors with high risk factor values may be less susceptible to atherogenesis. An alternative explanation is that the age-related changes in the predictive power of CHD risk factors may reflect biochemical and physiological changes, which are associated with the aging process per se, that alter an individuals atherogenic potential. On average, these age-dependent changes may differ between these subpopulations.
There is also evidence that variation in the genetic susceptibility of CHD reflected by measures of variation in the Apo E gene may vary among different subgroups of individuals. In our earlier Fig. 3 . In this paper we have performed a stratified risk assessment. Here we illustrate how different strata are defined. The purpose of the graph is to help visualize how the information obtained in this study can be employed in public health (level A) and in clinical (level E) practice. The letters B, C, and D refer to the levels where the splits are made in area of residence, age, and the Apo E genotype, respectively. (10) . The odds of CHD death during a 5-year follow-up in the carriers of the high risk o4/3 genotype were approximately 2.5 higher than in the carriers of the o3/3 genotype in the Southwestern cohort while in the Eastern cohort the respective ratio was 1.5. In contrast, in the Eastern cohort the odds of CHD death was approximately 7.5 times higher in the carriers of two rare o4/2 and o4/4 genotypes when compared with carriers of the o3/3 genotype. Consistent with these earlier observations, comparisons of the disease-specific survival curves in the present study demonstrate an excess of CHD mortality among the carriers of the o4/3 genotype as compared with carriers of the o3/3 genotype. The observed difference was statistically significant in the Southwestern cohort but not in the Eastern cohort. Our earlier observation that the relative frequency of the o4 allele was lower in the Eastern cohort than in the Southwestern cohort (29) suggests that a fraction of the geographic differences in the predictive power of the o4/3 genotype in this study may reflect a higher selective mortality against the o4 allele in the past in the Eastern cohort than in the Southwestern cohort.
Carriers of the o4 allele are hypothesized to be more prone to CHD than individuals who do not carry this allele because on average they have higher serum total cholesterol levels (3, 4) . Consistent with this hypothesis both the average serum total cholesterol level and its intragenotypic variation were higher in the carriers of the o4/3 genotype than in the carriers of the o3/3 genotype in our study in both cohorts. The difference in the interindividual variance of serum total cholesterol level between genotypes was statistically significant in the Southwestern cohort. Our observation that the CHD mortality rate was higher in the o4/3 genotype than in the o3/3 genotype in this cohort may thus be a consequence, at least in part, of a larger proportion of individuals with hypercholesterolemia among those with the o4/3 genotype, which is evident from the significantly greater dispersion of serum total cholesterol level in the Southwestern cohort.
Influence of the two most common Apo E genotypes on predictive utility of known risk factors within population and age-defined strata Most genetic studies assume that individuals with different genotypes respond similarly to exposures to internal (epigenetic and background genotype effects) and external (ecological) environments (30) . The goal of such studies is to identify genetic polymorphisms that have an independent influence on interindividual variation in the risk of disease. Only a few studies have been carried out with the intention of characterizing the contribution of genetic variation to interindividual differences in the relationships between various risk factors and of differences in the responses to exposures to internal and/or external environments. The biological fact that the contribution of any genetic or environmental variation to the variation in the risk of CHD must be translated through variation in, and covariation between, various biochemical and physiological risk factors suggests, however, that knowledge about the other aspects of the genetic architecture of CHD may be as important for risk assessment as is the knowledge about the average genotypic differences in the risk factor levels and in the risk of the disease. This reality is demonstrated by the influence of the Apo E polymorphism on covariation between lipid and lipoprotein traits (9) . The proportion of the individuals that exceed a threshold for high risk determined by multiple traits is different in different genotype groups even when the average levels of the risk factors may not differ. Recent evidence that the association between the amount of coronary calcification (an index of atherosclerosis) and plasma lipid levels may be different in different Apo E genotypes (31) documents the importance of the Apo E genotypes in determining the biological context in which the atherosclerotic process is occurring. Our study further documents that the statistical relationship between the risk of CHD death and established risk factors such as age, BMI, serum total and HDL cholesterol level, and tobacco smoking in elderly men may be different in different Apo E genotypes. However, since the influences of the Apo E genotypes on this relationship for a particular risk factor (e.g., BMI) were different in the Eastern and the Southwestern cohorts, our study suggests statistical interactions between genotype variation and variation in measures of risk that are indexed by area of residence.
Clinical and public health implications of our observations
In clinical practice, knowledge about risk factor levels is widely used to identify individuals who are at increased risk. High risk individuals are considered to be candidates for lifestyle alterations and related therapeutic interventions. The utility of genetic information both at the clinical level (level E, Fig. 3 ) and at the public health level (level A, Fig.  3 ) depends on whether it improves risk assessment.
Our study suggests that from the risk assessment point of view an important benefit of genetic knowledge is that a trait may be a significant predictor of a disease outcome only in individuals with a particular geno(me)type, even though it is not identified as a predictor in studies of the population at large. For instance, BMI is a well-known risk factor that has been positively associated with the risk of CHD in some populations (1, 2, 25) but not in others (1, 2). We did not identify BMI as a predictor of CHD death in elderly Finnish men either in the Eastern or the Southwestern cohort in this study nor in our earlier study (10) . However, in the present study variation in BMI was significantly associated with variation in the risk of CHD death both in the o3/3 (Pr=0.016) and the o4/3 (Pr =0.057) genotype groups in the Southwestern cohort. The estimate of the slope was positive in the former genotype group and negative in the latter genotype group, indicating that in Southwestern Finland the risk of CHD death increases with increasing BMI in elderly men with the o3/3 genotype, while the relative risk declines with increasing BMI in their counterparts with the o4/3 genotype. Since weight reduction is expected to lower the risk of CHD in obese individuals (32, 33) , a therapeutic implication of our result is that obese elderly men in the o3/3 genotype group in Southwestern Finland are targets for intensified weight reduction intervention(s).
A statistically significant decline in the risk of CHD death with advancing BMI (e.g., in elderly men with the o4/3 genotype in Southwestern Finland) is an unexpected observation that has no obvious explanation. One possibility is that a combination of obesity and the o4/3 genotype, both of which are associated with a highly atherogenic risk factor profile, has been extremely deleterious for middle-aged men in the Southwestern cohort where the CHD mortality rate has otherwise been low in the past. Alternatively, there would have to be other, unmeasured factors indexed by low BMI, which together with the o4/3 genotype increase the risk of CHD death in elderly men, and which have persisted in the Southwestern cohort where the CHD mortality rate has been low in the past but not in the Eastern cohort where the CHD mortality rate has been high. In any case, these findings serve as a document to why we failed to identify BMI as a predictor of CHD death in our earlier studies of the same cohort when the contribution of the Apo E genotypes was not considered.
In conclusion, a major finding of this study is that in elderly Finnish men the two common Apo E genotypes, together with the area of residence, serve to define contexts in which known risk factors such as age, BMI, serum total and HDL cholesterol, and tobacco smoking are operating in a different manner to determine the risk of CHD death. Although the first-order interactions reported here can reflect only a fraction of the complex pathobiology of CHD, they are consistent with the fact that CHD death is an emergent property of complex interactions between many genetic and environmental factors. Our observations make clear that to understand this complex pathobiology it is incumbent that we focus on the interactions between agents involved in causality rather than seeking their independent invariant properties. Stratified risk assessment serves as a strategy that takes advantage of the prognostic importance of these interactions. Identification of prognostically important strata, such as those defined by area of residence, age, and the Apo E genotype in this study, can result in a more precise risk assessment and ultimately improve clinical and public health strategies to prevent the disease both at individual and population levels.
